Finnish Start-up Emerges Post Merck/Schering-Plough Merger

September 22, 2011

Merck & Co Inc. (MRK) out-licensed a portfolio of gene therapy products into a new Finnish company, FKD Therapies OY, which was co-founded by Nigel Parker, former CEO of UK gene therapy specialist firmArk Therapeutics plc.

Since its formation in February, FKD has raised $16 million in private funding underwritten by German firm Wolbern Invest, with backing from Finland’s public funding agency for technology and innovation, TEKES.

Read more: http://seekingalpha.com

Recent related articles

Nexstim attracts additional equity financing – over EUR 13 million now raised in latest round

Nexstim Oy, a medical device company commercializing non-invasive brain diagnostic and therapy technologies,  announced in …

Greater Helsinki promotes neuroscience related R&D and business opportunities

One of GHP’s key operations in 2010 is marketing and promotional support of the Finnish …